Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Société Générale Major Shareholding Notification 2020

Nov 16, 2020

1671_mrq_2020-11-16_a80d7674-a718-405e-b371-99026cfea3d7.html

Major Shareholding Notification

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 3995F

Societe Generale SA

16 November 2020

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1) Société Générale S.A.
Company dealt in Willis Towers Watson plc
Class of relevant security to which the dealings being disclosed relate (Note 2) US$0.000304635 ordinary shares
Date of dealing 13/11/2020

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long Short
Number (%) Number (%)
(1) Relevant securities 429,396 0.33 1,611 0.00
(2) Derivatives (other than options) 1,490 0.00 12,296 0.01
(3) Options and agreements to purchase/sell 0 0.00 0 0.00
Total *1,552,877 *1.20 13,907 0.01

* Include the holding of 1,121,991 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security: Long Short
Number (%) Number (%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale Number of relevant securities Price per unit USD (Note 5)
Purchase 106 203.8
Purchase 41 203.8
Purchase 1 207.4
Purchase 16 207.4
Purchase 100 206.84
Purchase 28 206.94
Purchase 721 206.81
Purchase 2,915 206.81
Sale 2 203.8
Sale 6 207.31
Sale 28 207.31
Sale 53 204.71
Sale 47 204.71
Sale 66 207.31
Sale 100 205.45
Sale 13 206.62
Sale 87 206.62
Sale 27 207.4
Sale 100 205.19
Sale 13 207.4
Sale 60 207.4
Sale 69 205.01
Sale 17 207.29
Sale 23 207.29
Sale 60 207.29
Sale 83 205.28
Sale 60 207.36
Sale 20 207.36
Sale 20 207.36
Sale 31 205.01
Sale 6 206.66
Sale 5 206.66
Sale 9 206.66
Sale 51 206.66
Sale 19 206.66
Sale 10 206.66
Sale 4 206.47
Sale 42 206.47
Sale 54 206.47
Sale 76 206.94
Sale 24 206.94
Sale 2 206.74
Sale 20 206.74
Sale 47 206.74
Sale 31 206.74
Sale 100 206.96
Sale 4 207.29
Sale 100 205.97
Sale 100 207.3
Sale 100 206.81
Sale 100 206.81
Sale 3 205.02
Sale 100 206.66
Sale 84 206.76
Sale 55 207.43
Sale 16 206.76
Sale 1 207.25
Sale 99 207.25
Total Purchases 3,928
Total Sales 2,247

(b)      Derivatives transactions (other than options transactions)

Product name,

e.g. CFD
Nature of transaction

(Note 6)
Number of relevant securities

(Note 7)
Price per unit USD

(Note 5)
CFD Increased short 2,915 206.81
Euro Medium Term Note Increased Long 3 205.02

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name,

e.g. call option
Writing, selling, purchasing, varying etc. Number of securities to which the option relates (Note 7) Exercise price Type, e.g. American, European etc. Expiry date Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name,

e.g. call option
Number of securities Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)
Details Price per unit

(if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the 

voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            No

Date of disclosure 16/11/2020
Contact name Société Générale - Disclosure team
Telephone number +33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEFIFEDLILRLII